A study using gene expression, DNA copy number, somatic and germline mutation data of BC, showed TNBC (and HER2+) to have high immune gene expression and lower clonal heterogeneity as compared to other BC subtypes (Safonov et al., 2017). The gene discussed is ERBB2; the disease is breast cancer.